All Oncology News

The development of ZW171 for gynecologic, thoracic, and GI cancers is being discontinued.

Raji Shameem, MD, discusses the significance of the FDA approval of NALIRIFOX and first-line treatment selection in metastatic pancreatic cancer.

Rilzabrutinib has been approved by the FDA for persistent or chronic immune thrombocytopenia after an insufficient response to prior therapy.

Health services company recognizes joint care offered through collaboration with Roswell Park Oishei Children’s Hospital.

The FDA scheduled a Type A meeting with the developer of RP1 to discuss the CRL that was granted to RP1 plus nivolumab for advanced melanoma.

China’s NMPA approved zongertinib tablets for unresectable, locally advanced or metastatic, previously treated NSCLC with HER2 mutations.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The director of the Hematology and Oncology Fellowship Program at Weill Cornell Medicine details how fellows can identify and maximize research opportunities.

TT125-802 has received FDA fast track designations in EGFR+ and KRAS G12C+ advanced NSCLC.

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.

The European Medicines Agency has granted orphan drug designation to OXC-101 for the treatment of acute myeloid leukemia.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The FDA granted breakthrough device designation to the Haystack MRD ctDNA liquid biopsy for stage II colorectal cancer.

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

Andrea Necchi, MD, discusses how initial findings from the SURE-02 study indicate the potential for bladder preservation over cystectomy in MIBC.

Researchers have developed the first genome-wide CRISPR screening tool for primary human natural killer cells.

The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

The combination of anlotinib plus chemotherapy has been approved in China for the treatment of patients with advanced soft tissue sarcoma.

A phase 1/2 trial met its primary end point of ORR with sonrotoclax in patients with relapsed/refractory MCL.

The FDA has approved a 3-month version of leuprolide mesylate for patients with advanced prostate cancer.

Tari A. King, MD, FACS, FSSO, FASCO, discusses the importance of multidisciplinary breast cancer management and the potential to de-escalate treatment.

As the FDA aims to reduce drug review times, the 15% tariff rate imposed on pharmaceuticals from Europe could affect drug access in the oncology space.

Annamycin plus cytarabine produced a potential overall survival benefit in acute myeloid leukemia.

Samina Hirani, MD, discusses the evolving first-line treatment paradigm for patients with DLBCL and the unprecedented findings from the POLARIX trial.

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

In an OncLive® Peer Exchange, 4 panelists discuss navigating fixed-duration vs continuous therapy in CLL.